echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Large varieties with annual sales of more than 1 billion yuan were greatly reduced by 46%

    Large varieties with annual sales of more than 1 billion yuan were greatly reduced by 46%

    • Last Update: 2019-09-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [product information of pharmaceutical network] on September 17, Heilongjiang Medical Insurance Bureau issued the notice on the price reduction of ibuprofen injection of Chengdu Yuandong biopharmaceutical Co., Ltd (hereinafter referred to as the notice) According to the notice, Heilongjiang Medical Insurance Bureau received the independent price reduction application from Chengdu Yuandong biology Co., Ltd., the reference price of ibuprofen injection (specification 4ml: 0.4g) was reduced from 105.8 yuan / piece to 57.6 yuan / piece, a decrease of 45.6%; the reference price of ibuprofen injection (specification 8ml: 0.8g) was reduced from 180 yuan / piece to 97.92 yuan / piece, a decrease of 45.6%, and the new online price was implemented from the date of publication Previously, CDE released the 23rd batch of generic reference preparations, involving 318 drugs (by serial number), 171 of which belong to injection, involving 87 varieties (by drug name) Among the 87 varieties, only one enterprise passed or deemed to have passed the consistency evaluation, which is ibuprofen injection of Chengdu Yuandong biological Co., Ltd the product is applied for listing in imitation of three categories, and is deemed to have passed the consistency evaluation after being approved for production Ibuprofen injection is a non steroidal injection used in pediatric antipyretic and analgesic double indications In response to the second round of inquiries from Shanghai Stock Exchange in May this year, Yuandong Bio said that it spent nine years to invest nearly ten million yuan in the development of ibuprofen injection, and obtained "ibuprofen injection composition and preparation method" through a large number of process research and preparation innovation; although there are dozens of enterprises following up the research and development, it is difficult due to technical difficulties and clinical research So far, only the company has been approved to be the first one to go on the market, and the first one to pass the consistency evaluation of quality and efficacy of generic drugs As of the signing date of the prospectus, ibuprofen injection of Yuandong bio is the first imitated listed product, and the listing time is 2018 There is no relevant competitive product in China, so the market share of the product is 100% According to the data query of the State Food and drug administration, there are two domestic approvals for ibuprofen injection, all of which are held by Chengdu Yuandong Bio Technology Co., Ltd and approved by the State Food and Drug Administration for production on July 31, 2018 At present, Hangzhou Minsheng, Jilin 4th Ring Road, Jiangsu Wuzhong Suzhou pharmaceutical factory and other pharmaceutical enterprises are applying for ibuprofen injection Ibuprofen is a single product with annual sales of more than 1 billion yuan in retail pharmacies According to the data of minenet, in 2017, the sales volume of ibuprofen in the terminals of public medical institutions in China was 1.019 billion yuan Before the approved production of the products of Chengdu Yuandong biopharmaceutical Co., Ltd., there was no injection on the market in China There are 601 domestic approvals for this variety The enterprises holding the approvals include Kangenbei, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd., sunflower Pharmaceutical Co., Ltd., xinlitai, Harbin Pharmaceutical Group and other well-known pharmaceutical enterprises It can be seen that the competition for this variety is very fierce However, it is also mentioned in the industry that, compared with oral preparations, injection (excluding slow and controlled release preparations, suspensions, oils, liposomes and other special preparations) does not need to be tested in consistency evaluation, which costs less, but the requirements in prescription technology, excipients, packaging, process control and other aspects are relatively strict, and it is more difficult to pass the consistency evaluation The approval of Chengdu Yuandong biopharmaceutical Co., Ltd not only proves that the product is qualified, but also helps to further stabilize the market Previously, the industry speculated that ibuprofen injection (Chengdu Yuandong) is expected to participate in the second round of centralized purchase and be selected into the list of the second batch of purchased varieties with volume, which will become a beneficiary enterprise This time, Chengdu Yuandong decided to reduce the price of the variety or make preparations for participating in the collective purchase.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.